Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma

Arnold Bolomsky, Smriti Kanangat, Michele Ceribelli, Kristina Rinaldi, Lin Zhang, Elizabeth Hill, Jagan R. Muppidi, Craig J. Thomas, Ryan M. Young

Blood (2024) 144 (Supplement 1): 763.

https://doi.org/10.1182/blood-2024-208485

Published: 2024

Journal Articles

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7059.

https://doi.org/10.1182/blood-2024-201563

Published: 2024

Journal Articles

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Blood (2023) 142 (Supplement 1): 337.

https://doi.org/10.1182/blood-2023-181811

Published: 2023

Journal Articles

Exceptional Response to BTK Inhibitors in Aggressive Lymphomas Linked to Chronic Selective Autophagy

Blood (2023) 142 (Supplement 1): 850.

https://doi.org/10.1182/blood-2023-190851

Published: 2023

Journal Articles

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Benjamin Diamond, Dickran Kazandjian, Marios Papadimitriou, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Elizabeth Hill, Romanos Sklavenitis-Pistofidis, Kylee H Maclachlan, Ryan M. Young, Saad Z Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Gareth J. Morgan, Francesco Maura, Ola Landgren

Blood (2023) 142 (Supplement 1): 757.

https://doi.org/10.1182/blood-2023-181817

Published: 2023

Journal Articles

Epitope Editing in Hematopoietic Cells Enables CD45-Directed Immune Therapy

Nils Wellhausen, Austin K Rennels, Stefanie Lesch, Sangya Agarwal, Brooke Charria, Grace Choi, Regina M Young, Christopher Garcia, Carl H June, Saar Gill

Blood (2022) 140 (Supplement 1): 862–864.

https://doi.org/10.1182/blood-2022-158684

Published: 2022

Journal Articles

Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma

Grace M. Pindzola, Raud Razzaghi, Rachel N. Tavory, Hang T. Nguyen, Vivian M. Morris, Moyi Li, Shreya Agarwal, Bonnie Huang, Takaharu Okada, Hans C. Reinhardt, Gero Knittel, Hamid Kashkar, Ryan M. Young, Stefania Pittaluga, Jagan R. Muppidi

Blood (2022) 140 (10): 1119–1131.

https://doi.org/10.1182/blood.2022015926

Published: 2022

Includes: Supplemental data

Journal Articles

Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis

Frits I. Mulder, Floris T. M. Bosch, Annie M. Young, Andrea Marshall, Robert D. McBane, II, Tyler J. Zemla, Marc Carrier, Pieter Willem Kamphuisen, Patrick M. M. Bossuyt, Harry R. Büller, Jeffrey I. Weitz, Saskia Middeldorp, Nick van Es

Blood (2020) 136 (12): 1433–1441.

https://doi.org/10.1182/blood.2020005819

Published: 2020

Includes: Supplemental data

Journal Articles

Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia

Melat T. Gebru, Jennifer M. Atkinson, Megan M. Young, Lijun Zhang, Zhenyuan Tang, Zhenqiu Liu, Pinyi Lu, Christopher M. Dower, Longgui Chen, Charyguly Annageldiyev, Arati Sharma, Yuka Imamura Kawasawa, Zhongming Zhao, Barbara A. Miller, David F. Claxton, Hong-Gang Wang

Blood (2020) 136 (9): 1067–1079.

https://doi.org/10.1182/blood.2019003124

Published: 2020

Includes: Supplemental data

Journal Articles

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Blood (2019) 134 (Supplement_1): 247.

https://doi.org/10.1182/blood-2019-131024

Published: 2019

Journal Articles

KLHL14 Is a Tumor Suppressor in Diffuse Large B-Cell Lymphoma

Jaewoo Choi, PhD, James D Phelan, PhD, Ryan M. Young, PhD, Thomas Oellerich, MD, Da Wei Huang, MD, Arthur L Shaffer, PhD, Louis Staudt, MD

Blood (2019) 134 (Supplement_1): 2766.

https://doi.org/10.1182/blood-2019-125137

Published: 2019

Journal Articles

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1863.

https://doi.org/10.1182/blood-2019-131515

Published: 2019

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

The Total Direct Cost of Healthcare in the United States in Patients with Sickle Cell Disease: A Propensity Score Matched Analysis

Jonathan Salcedo, MA, Colin M Young, PhD, Jenniffer Bulovic, MD MPH

Blood (2019) 134 (Supplement_1): 4671.

https://doi.org/10.1182/blood-2019-122597

Published: 2019

Journal Articles

Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones

J. Joseph Melenhorst, PhD, David L. Porter, MD, Lifeng Tian, PhD, Simon F Lacey, PhD BS, Christopher L Nobles, PhD, Joseph A Fraietta, PhD, Noelle V. Frey, MD, Irina Kulikovskaya, Minnal Gupta, Regina M Young, PhD, David E Ambrose, BS, Don L. Siegel, MD PhD, Frederic D Bushman, PhD, Carl H June, MD

Blood (2018) 132 (Supplement 1): 699.

https://doi.org/10.1182/blood-2018-99-117390

Published: 2018

Journal Articles

PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells

Luca Bernabei, Alfred L. Garfall, MD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD BS, Edward A. Stadtmauer, MD FACP, Dan T. Vogl, MD, Vanessa Gonzalez, Gabriela Plesa, MD, Regina M Young, PhD, Adam Waxman, MD, Bruce L Levine, PhD, Carl H June, MD, Michael C. Milone, MD PhD, Adam D. Cohen, MD

Blood (2018) 132 (Supplement 1): 1973.

https://doi.org/10.1182/blood-2018-99-119514

Published: 2018

Journal Articles

Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Adam D. Cohen, MD, J. Joseph Melenhorst, PhD, Alfred L. Garfall, MD, Simon F Lacey, PhD BS, Megan Davis, PhD, Dan T. Vogl, MD, Lifeng Tian, PhD, Vanessa Gonzalez, Iulian Pruteanu, PhD, Anne Marie Nelson, Gabriela Plesa, MD, Adam Waxman, MD, Regina M Young, PhD, Bruce L Levine, PhD, Carl H June, MD, Edward A. Stadtmauer, MD FACP, Michael C. Milone, MD PhD

Blood (2018) 132 (Supplement 1): 1974.

https://doi.org/10.1182/blood-2018-99-119665

Published: 2018

Journal Articles

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 3181.

https://doi.org/10.1182/blood.V130.Suppl_1.3181.3181

Published: 2017

Journal Articles

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 1319.

https://doi.org/10.1182/blood.V130.Suppl_1.1319.1319

Published: 2017

Journal Articles

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Marco Ruella, MD, Shannon L Maude, MD PhD, Boris Engels, PhD, David M. Barrett, Noelle Frey, MD, Katherine T Marcucci, PhD, Olga Shestova, PhD, Nathan Singh, MD, Jessica Perazzelli, PhD, David A Christian, PhD, Dana Haagen, BS, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Jennifer Brogdon, PhD, Regina M Young, PhD, David L Porter, MD, Carl H June, MD, Stephan A Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 807.

https://doi.org/10.1182/blood.V130.Suppl_1.807.807

Published: 2017

NARROW

Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Exceptional Response to BTK Inhibitors in Aggressive Lymphomas Linked to Chronic Selective Autophagy

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Epitope Editing in Hematopoietic Cells Enables CD45-Directed Immune Therapy

Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma

Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis

Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

KLHL14 Is a Tumor Suppressor in Diffuse Large B-Cell Lymphoma

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

The Total Direct Cost of Healthcare in the United States in Patients with Sickle Cell Disease: A Propensity Score Matched Analysis

Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones

PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells

Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only